$LXEO

Lexeo Therapeutics, Inc.

Lexeo Therapeutics is a clinical-stage genetic medicine company developing gene therapies for cardiovascular diseases and other conditions with genetic causes. Its cardiovascular pipeline includes LX2006 for Friedreich ataxia cardiomyopathy, LX2020 for PKP2-associated arrhythmogenic cardiomyopathy, LX2021 for DSP cardiomyopathy and related heart conditions, and LX2022 for hypertrophic cardiomyopathy caused by TNNI3 mutations. LX2006 and LX2020 are being evaluated in Phase 1/2 clinical trials. The company also develops gene therapy candidates for APOE4-associated Alzheimer’s disease, including LX1001, which has completed a Phase 1/2 clinical trial. Lexeo’s candidates are designed to deliver functional genes or other genetic material to target cells, primarily through intravenous gene therapy. It uses an Sf9-baculovirus system to manufacture its gene therapy candidates and retains exclusive worldwide development and commercialization rights to its programs. Lexeo Therapeutics is headquartered in New York, New York.

AlphAI earnings readSecond Quarter 2026 · AUG 12Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational HighlightsVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

13
0
2

No SEC Form 4 filings for $LXEO in the last 30 days.

See all $LXEO insider activity →
Med

Biotech Stocks Move Higher: CGON +18%, CNSP +13%, LXEO +8%, XRTX +7%

CG Oncology (CGON) +18% after positive Phase 3 bladder cancer trial data. CNS Pharmaceuticals (CNSP) +13% on pipeline acquisition progress. Lexeo Therapeutics (LXEO) +8% with encouraging gene therapy results. XORTX Therapeutics (XRTX) +7% after completing clinical drug manufacturing for gout program.

Why is Lexeo Therapeutics stock surging today?

Lexeo Therapeutics (LXEO) stock rose 23.7% in pre-market trading after reporting positive interim data from its HEROIC-PKP2 trial for LX2020, showing 80% reduction in NSVT. The FDA indicated openness to using NSVT as a surrogate endpoint. Analysts raised price targets, with Raymond James increasing to $42. The company reported $219.1M in cash, funding operations into 2028, despite a Q3 net loss of $38.3M.

LXEO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 15 news stories mentioning LXEO (Lexeo Therapeutics, Inc.). Coverage has skewed bullish: 13 bullish, 0 neutral, and 2 bearish.

Recent LXEO coverage spans financial news, market movers and earnings.

What's driving LXEO

AlphAI scores every news story that mentions LXEO with an AI model for sentiment and relevance, and aggregates insider trades from Lexeo Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $LXEO

Score
$LXEOHighAI 9/10

Why is Lexeo Therapeutics stock surging today?

Lexeo Therapeutics (LXEO) stock rose 23.7% in pre-market trading after reporting positive interim data from its HEROIC-PKP2 trial for LX2020, showing 80% reduction in NSVT. The FDA indicated openness to using NSVT as a surrogate endpoint. Analysts raised price targets, with Raymond James increasing to $42. The company reported $219.1M in cash, funding operations into 2028, despite a Q3 net loss of $38.3M.

$LXEOMedAI 9/10

Lexeo reports interim trial results for PKP2-ACM gene therapy

Lexeo Therapeutics (NASDAQ:LXEO) reported interim Phase I/II trial data for LX2020, a gene therapy for PKP2-ACM. High-dose participants showed 80% reduction in non-sustained ventricular tachycardia and 44% reduction in premature ventricular contractions. The treatment was generally well-tolerated. Lexeo expects to finalize pivotal study design in 2027. Q3 2026 net loss was $38.3M, with $219.1M in cash expected to fund operations into 2028.

Lexeo Therapeutics 3Q 2026: EPS ($0.43) — 10-Q Summary

Lexeo Therapeutics reported a net loss of $38.3M in Q3 2026, up 88.8% YoY, with no revenue. Costs increased due to the Mantle acquisition, development milestones, and clinical trials. LX2006 and LX2020 trials progressed, and cash runway extends into 2028. According to the company, the Mantle acquisition added Friedreich ataxia assets.

$LXEOHighEarnings

Lexeo Therapeutics, Inc. (LXEO): Results of Operations and Financial Condition

Lexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventri

$LXEOMedAI 8/10

Oppenheimer reiterates Lexeo Therapeutics stock rating on trial data

Oppenheimer maintained an Outperform rating and $20 price target for Lexeo Therapeutics (LXEO) after positive clinical trial data for LX2006. The stock is up 16% this week but down 46% over six months. The firm cited strong efficacy signals and market potential. Lexeo also completed a $21.3M acquisition of Mantle Therapeutics, adding new programs. Analysts from Baird, Raymond James, and Stifel also reiterated positive ratings with higher price targets.

Stifel reiterates Buy rating on Lexeo Therapeutics stock at $17

Stifel reiterated its Buy rating on Lexeo Therapeutics (LXEO) with a $17 price target, citing management's confidence in achieving a 15% effect size in a pivotal study. The stock trades at $3.53, below the analyst consensus range of $9 to $30. Lexeo completed the acquisition of Mantle Therapeutics for $8.3 million, adding new programs to its Friedreich’s ataxia portfolio. Baird and Raymond James also reiterated positive ratings with higher price targets.

Related tickers